Contract facts
FederalNo full NAICS 424210 intel page yet. Browse NAICS intelligence
4566006268!ENTYVIO 300 MG VIALS is a federal award for Dla Troop Support held by Dms Pharmaceutical Group Inc. Estimated value $246K ($246K obligated). Current period of performance ends Oct 21, 2024. Place of performance: PARK RIDGE IL.
Recompete timing
PublicCurrent PoP ended Oct 21, 2024 (669 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordDms Pharmaceutical Group Inc — $737.3M obligated across 100,503 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract SPE2DB24FPRQ4?
SPE2DB24FPRQ4 (4566006268!entyvio 300 MG VIALS) is a Dla Troop Support award with a potential value of $246K, currently held by Dms Pharmaceutical Group Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded SPE2DB24FPRQ4?
Dla Troop Support awarded SPE2DB24FPRQ4 to Dms Pharmaceutical Group Inc (potential $246K).
Who is the incumbent on SPE2DB24FPRQ4?
Dms Pharmaceutical Group Inc is the incumbent with $737.3M across 100503 related awards in SCOUT’s public footprint. The current period of performance ends Oct 21, 2024.
When does Dms Pharmaceutical Group Inc’s SPE2DB24FPRQ4 come up for recompete?
SCOUT tracks a period-of-performance end of Oct 21, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.